CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA by Ugo Testa, Elvira Pelosi, Germana Castelli

“…Various immunotherapy strategies have emerged as an efficacious approach for the treatment of MM, including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor T (CAR-T) cells. Anti-B-cell maturation antigen (BCMA) CAR-T cells have revolutionized the treatment of MM patients with relapsed/refractory disease and their clinical use was approved for the treatment of these patients. …”
Get full text

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects by Yelei Guo, Yao Wang, Weidong Han

“…Recent studies have highlighted the successes of chimeric antigen receptor-modified T- (CART-) cell-based therapy for B-cell malignancies, and early phase clinical trials have been launched in recent years. …”
Get full text

Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells by Pengju Wang, Yiyi Wang, Xiaojuan Zhao, Rui Zheng, Yiting Zhang, Ruotong Meng, Hao Dong, Sixin Liang, Xinyi He, Yang Song, Haichuan Su, Bo Yan, An-Gang Yang, Lintao Jia

“…Abstract The excessive cytokine release and limited persistence represent major challenges for chimeric antigen receptor T (CAR-T) cell therapy in diverse tumors. …”
Get full text

Defining ‘Intention’ in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy by Charles J. Milrod, Rebecca Steuer, Ari Pelcovits

Get full text

Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma by Chengcheng Zhang, Linling Wang, Qianzhen Zhang, Junjie Shen, Xia Huang, Meiling Wang, Yi Huang, Jun Chen, Yanmin Xu, Wenxu Zhao, Yanan Qi, Yunyan Li, Yanjiao Ou, Zhi Yang, Cheng Qian

Subjects: “…chimeric antigen receptor T cells…”
Get full text

Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma by Hui-Ju Hsieh, Ryan Urak, Mary C. Clark, Larry W. Kwak, Stephen J. Forman, Xiuli Wang

“…Previously, we have shown that AKT Inhibitor VIII, a selective AKT-1/2 inhibitor, during chimeric antigen receptor (CAR) T cell manufacturing, improves CAR T cell function in preclinical models. …”
Get full text

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review by Joseph Sassine, Emily A. Siegrist, Roy F. Chemaly

“…In this narrative review, we explore the burden and risk factors of various herpesvirus infections in patients receiving chimeric antigen receptor T-cell (CAR-T) therapy or bispecific antibodies (BsAb) for the treatment of hematologic malignancies. …”
Get full text

Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies by Chenyun Zhang, Haizhou Liu

“…In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has made groundbreaking progress in the treatment of various cancer types, particularly hematological malignancies. …”
Get full text

Corrigendum: Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma by Chengcheng Zhang, Linling Wang, Qianzhen Zhang, Junjie Shen, Xia Huang, Meiling Wang, Yi Huang, Jun Chen, Yanmin Xu, Wenxu Zhao, Yanan Qi, Yunyan Li, Yanjiao Ou, Zhi Yang, Cheng Qian

Subjects: “…chimeric antigen receptor T cells…”
Get full text

Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024Keypoints by Bastian Engel, David N. Assis, Mamatha Bhat, Jan Clusmann, Joost PH. Drenth, Alessio Gerussi, María-Carlota Londoño, Ye Htun Oo, Ida Schregel, Marcial Sebode, Richard Taubert

Subjects: Get full text

CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist? by Marie José Kersten, Maria Theresa Kuipers

“…CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases. …”
Get full text

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas by Gohar S. Manzar, Chelsea C. Pinnix, Stephanie O. Dudzinski, Kathryn E. Marqueen, Elaine E. Cha, Lewis F. Nasr, Alison K. Yoder, Michael K. Rooney, Paolo Strati, Sairah Ahmed, Chijioke Nze, Ranjit Nair, Luis E. Fayad, Michael Wang, Loretta J. Nastoupil, Jason R. Westin, Christopher R. Flowers, Sattva S. Neelapu, Jillian R. Gunther, Bouthaina S. Dabaja, Susan Y. Wu, Penny Q. Fang

Subjects: Get full text

Loop33 × 123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia by Haotian Ma, Zhifeng Yan, Runxia Gu, Yingxi Xu, Shaowei Qiu, Haiyan Xing, Kejing Tang, Zheng Tian, Qing Rao, Min Wang, Jianxiang Wang

Subjects: Get full text

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment by Rahul Navab, Pragyat Futela, Verkha Kumari, Jayesh Valecha, Ramansh Bandhu Gupta, Rohit Jain

“…Despite traditional treatments, MM remains incurable, necessitating innovative therapeutic approaches. Chimeric Antigen Receptor (CAR) T-cell therapy and Bispecific T-cell engagers (BiTEs) are emerging immunotherapies showing promise in MM treatment. …”
Get full text

SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report by Hongyan Liu, Colleen Callahan, Shannon L Maude, Kevin Owen McNerney, Rebecca M Richards, Paibel Aguayo-Hiraldo, Friso G Calkoen, Julie-An Talano, Amy Moskop, Adriana Balduzzi, Jennifer Krajewski, Hema Dave, Anant Vatsayan, Yimei Li, Kara Lynn Davis

“…Patients undergoing chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory B-cell malignancies are uniquely immunosuppressed due to CAR T-mediated B-cell aplasia (BCA). …”
Get full text

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy by Xin Liu, Yang Du, Ningyan Zhang, Zhiqiang An, Wei Xiong, Yixiang Xu, Bingnan Yin, Yuqian Huang, Junjun Chu, Changsheng Xing, Chen Qian, Tianhao Duan, Helen Y Wang, John S. Yu, Rongfu Wang

“…Background The current therapeutic antibodies and chimeric antigen receptor (CAR) T cells are capable of recognizing surface antigens, but not of intracellular proteins, thus limiting the target coverage for drug development. …”
Get full text

Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults by Maike Breidenbach, Peter Bader, Andishe Attarbaschi, Claudia Rossig, Roland Meisel, Markus Metzler, Marion Subklewe, Fabian Mueller, Paul-Gerhardt Schlegel, Irene Teichert von Lüttichau, Jean-Pierre Bourquin, Gabriele Escherich, Gunnar Cario, Peter Lang, Ramona Coffey, Arend von Stackelberg, Semjon Willier, Brigitte Strahm, Christina Peters, Tobias Feuchtinger

“…Abstract Anti-CD19 chimeric antigen receptor T cells (CAR) are a well-established treatment option for children and young adults suffering from relapsed/refractory B-lineage acute lymphoblastic leukemia. …”
Get full text

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design by Haiying Qin, Nirali N Shah, Terry J Fry, Lila Yang, John A Chukinas, Samiksha Tarun, Marie Pouzolles, Christopher D Chien, Lisa M Niswander, Anthony R Welch, Sarah K Tasian, Naomi A Taylor

“…Background Successful development of chimeric antigen receptor (CAR) T cell immunotherapy for children and adults with relapsed/refractory acute myeloid leukemia (AML) is highly desired given their poor clinical prognosis and frequent inability to achieve cure with conventional chemotherapy. …”
Get full text

The nuclear factor-κ B inhibitor SN50 enhances the efficacy of B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy by Jinlan Long, Shufeng Xie, Wenjie Zhang, Weiyu Dou, Yixin Wang, Ruiheng Wang, Han Liu, Zhenshu Xu

Get full text

Peer Review of “Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Recurrent Glioblastoma: An Augmented Meta-Analysis of Phase 1 Clinical Trials (Preprint)” by Vanessa Fairhurst, Randa Salah Gomaa Mahmoud, Toba Olatoye, Sylvester Sakilay

Get full text